High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy.

"the clinical features were comparable between naive and neo groups or between neo-c neo-cr and neo-cri groups ( online supplemental table s4 ) 10 1136/jitc-2023-007847 supp2 supplementary data 10 1136/jitc-2023-007847 supp3 supplementary data figure 1 experiment overview and single-cell annotation of esophageal squamous cell carcinoma revealed by mass cytometry (a) study schema (created with biorender com) (b) t-sne plot of single cells colored by major cell types (c) t-sne plots demonstrating the expression of marker genes cd45 cd31 fap and ?"

"Competing interests: HWMvL reports research funding and/or medication supply from Bristol-Myers Squibb, Bayer Schering Pharma, Celgene, Janssen-Cilag, Lilly, Nordic Pharma, Philips Healthcare, Roche, Merck Sharp and Dohme, Servier, Incyte, and consultant/advisory board members for Lilly, Nordic Pharma, Bristol-Myers Squibb, Dragonfly, Merck Sharp and Dohme, Servier, outside the submitted work. The remaining authors have declared no conflicts of interest."

"Funding: This study was supported by National Natural Science Foundation of China (82072557, 81871882, 82372855), National Key Research and Development Program of China (2021YFC2500900), Shanghai Municipal Education Commission–Gaofeng Clinical Medicine Grant (20172005, the 2nd round of disbursement), Program of Shanghai Academic Research Leader from Science and Technology Commission of Shanghai Municipality (20XD1402300), Novel Interdisciplinary Research Project from Shanghai Municipal Health Commission (2022JC023), and Interdisciplinary Program of Shanghai Jiao Tong University (YG2023ZD04), and Shanghai Sailing Program (21YF1427100)."